Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 13/20 | 0.76 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.73 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.69 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | GPR183 | P32249 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6326677 | 1.00 | HCRTR2 (0.76) | HCRTR2HCRTR1HDAC8DPP8NPC1 | |
| SCHEMBL6324675 | 1.00 | HCRTR2 (0.76) | HCRTR2HCRTR1HDAC8DPP8NPC1 | |
| SCHEMBL1358772 | 0.83 | HDAC8 (0.97) | HDAC8DPP8KMT2AALDH1A1 | |
| SCHEMBL1358775 | 0.83 | HDAC8 (0.97) | HDAC8DPP8KMT2AALDH1A1 | |
| SCHEMBL6325198 | 0.82 | HCRTR2 (1.00) | HCRTR2HCRTR1NPC1KMT2AKDM4E | |
| SCHEMBL14392394 | 0.81 | DPP8 (1.00) | HCRTR2HCRTR1DPP8NPC1KMT2A | |
| SCHEMBL6428456 | 0.79 | HCRTR2 (0.76) | HCRTR2HCRTR1NPC1KMT2AKDM4E | |
| SCHEMBL18766747 | 0.78 | HCRTR2 (0.70) | HCRTR2HCRTR1NPC1KMT2AKDM4E | |
| SCHEMBL9667825 | 0.78 | CHRNA7 (0.69) | HCRTR2HCRTR1NPC1KMT2AKDM4E | |
| SCHEMBL9668362 | 0.78 | CHRNA7 (0.69) | HCRTR2HCRTR1NPC1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050148634-A1 | 1-N-Aminobenzimidazole derivatives | ZERIA PHARMACEUTICAL CO., LTD (JP) | 2005-07-07 | — | — | US | disclosed |
| US-6838465-B2 | N-acyltetrahydroisoquinoline derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-01-04 | — | — | US | disclosed |
| US-20040044031-A1 | N-acyltetrahydroisoquinoline derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
| EP-1288202-A1 | N-ACYLTETRAHYDROISOQUINOLINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044031-A1 | N-acyltetrahydroisoquinoline derivatives | HCRTR2, HCRTR1, OPRL1 | HCRTR2 1/4885HCRTR1 2/4885HDAC8 1080/4885 |
| US-20050148634-A1 | 1-N-Aminobenzimidazole derivatives | CYP1B1, CYP2E1, CYP1A1 | HCRTR2 4425/4885HCRTR1 4010/4885HDAC8 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.